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A bstract 
Ajulemic Acid Induces Cell Death in Retinobla toma Cell 
emil) A. Evans 
Retinoblastoma is a cancer of the retina affecting one in e\ ery 15.000-20.000 
births. It is normally diagnosed in infancy or early childhood and although it is treatable. 
enucleation is commonly required. Other treatments include radiation, photocoagulation, 
or cryotherapy and are often followed by chemotherap). ln an attempt to find an 
alternate method of treatment that lowers the frequency of enucleation and the 
serious side-effects resulting from current treatments, ajulemic acid (AJA). aS) nthetic 
derivative of Cannabis. has been used to treat retinoblastoma cells. Thus far. significant 
cell death has occurred among retinoblastoma cells that have been treated with AJA 
concentrations of as low as 50 ~-tM. We are also currently investigating how the AJA 
treatment of retinoblastoma cells compares with carboplatin treatment, one of the leading 
chemotherapy drugs currently used in treating retinoblastoma. 
ln trod uction 
Retinoblaslomu 
The purpose of our research was to investigate ajulemic acid's (AJA) ability to 
induce retinoblastoma cell death and to compare it V\ ith one current chemotherapy 
method of treatment, the drug carboplatin (CBP). 
Retinoblastoma (Rb) is a pediatric cancer that develops in the retina of the eye 
and is the most frequent primary eye grow1h found in infants and children (Blachford. 
2002). This disease occurs in nearly one out of every 15.000-20.000 live births world-
\\ide (Aerts, 2006). Rb usually occurs and is diagnosed before the age of 4 (Beers, 2003) 
I lov.ever, it can be identified in patients at the ages of 5-7 years (Murphree and Clark) an 
even more rarely in adulthood (Aerts. 2006). A consistenc) of cases among all races has 
been observed and there is no significant difference in the number of cases betvveen male 
or female or between incidences in the lefl or right eye (Kufe et al., 2003). In developed 
countries. there is a high survival rate for children with retinoblastoma: however children 
~ ith the disease in underdeveloped parts of the world rarely survive (Murphree and 
Clark). 
There are a variety of ways that retinoblastoma can present, but the most common 
signs are leukocoria, a white pupillaf) reflex, seen in 50% of patients and strabismus, 
crossed eyes, observed in 25% of patients (Blachford, 2002). Other symptoms may 
include red painful eye, poor vision, iris rubeosis (abnormal blood vessel gro~th of the 
iris), orbital cellulites (orbital tissue infection), hypopyon (pus in the eye), amblyopia 
("lazy eye"), congenital glaucoma, exophthalmia (eyeball protrusion) and heterochromia 
(difTerence in iris coloration) (Aertes, 2006: Blachford, 2002). 
Retinoblastoma develops in a few different \Vays. Endophytic growth, most 
common!) observed, refers to v.hen retinoblastoma grows into the vitreous cavity 
outward from the retina toward the eye's center. Gro'vth of the tumor into the choroid 
and away from the underside of the retina is referred to as exophytic gro~th. Exophytic 
growth is frequently associated with retinal detachment and the spread of the tumor into 
the choroid and optic nerve. A more uncommon growth pattern is known as diffuse 
infiltrating in which a mass is not formed, rather the tumor is dispersed throughout the 
retina (Murphree and Clark). 
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Retinoblastoma Etiology 
Retinoblastoma can be inherited or can occur sporadically. About 45% of cases 
are the nonhereditary form, or non-germinal, and approximately 55% of the cases are 
inherited. or germinaL in which there is an immediate family member 'vvho has previously 
been diagnosed with the disease (Aertes, 2006). The nonhereditary form nom1ally occurs 
unilaterally and is unifocal. a single tumor that affects one eye (Blachford. 2002). The 
hereditary form always presents either bilaterall) (affecting both eyes) or unilaterally and 
multifocal (multiple tumors in one eye). 
When the disease is inherited. a germline mutation has typically already occurred 
in one of the alleles of the retinoblastoma gene (RB-1) that codes for the protein pRB. If 
a person inherits one mutated allele and one normaJ allele. the person will not develop 
cancer as long as the normal allele does not become mutated. However. \\hen a somatic 
mutation of the second allele occurs. the gene v .. ill code or miscode for the defective pRB 
and cell division will no longer be regulated. This lack of regulation results in cancer. 
Instead of inheriting mutations. people with sporadic retinoblastoma have tv.·o 
independent somatic mutations occurring in both alleles of the RB-1 gene. Again. the 
correct coding of pRB is prevented and cancer resulrs. This idea that retinoblastoma is 
the result of two mutational events is known as Knudson's two hit hypothesis (Tobias and 
Black. 2002). 
Due to pRB 's involvement in other types of cancers as well as retinoblastoma, the 
patients that have a genninal mutation are at higher risks for developing nonocular 
neoplasms (Narins, 2000). Other cancers that are linked to a mutated RB-I gene include 
cancer of the breast. brain, or prostate. osteosarcoma. soft tissue sarcoma. leukemia and 
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other sporadic cancers. Another risk. for those '"'ith a germline mutation is .. trilateral 
retinoblastoma"' '"hich imohes a pediatric tumor in the midbrain (MacPherson, 2008). 
fhe cause of retinoblastoma has been linked to lo5s of function of the tumor 
suppressor retinoblastoma gene (RB-I) at chromosome location I 3q 14 (Tobias and 
Black). I"here are 27 exons that encode the RB-I gene ranging from 3 I to l ,889 base 
pairs (Claudio, et al., 2002). RB-1 codes for the protein pRB, a nuclear phosphoprotein 
that is part of a pathway for cell division regulation. differentiation, apoptosis. and other 
important processes (MacPherson. 2008). If pRB does not function correctly due to its 
absence or gene mutation. uncontrolled cell proliferation is occurs leading to the 
development of cancer (Brigham, 2000). J Jo,,e, er. recent studies have suggested an 
additional mutation is needed for retinoblastoma to present. 
There are three proteins that make up'' hat are kno'<m as the "pocket proteins:· 
fhcy include pRB. p107. and p103. Named for their pocket domain. they are important 
for binding E2f transcription factors and the) form part of a signal-transduction path"' a) 
k.nov.n as the RB pathway. These pocket proteins are similar in that all three consist of 
an amino-tcrn1inal domain. two conserved domains that male up the pocket region. a 
spacer region. and a carboxy-terminal domain. 1 he) differ in function and the specific 
E2f transcription factors that they bind to. Interestingly. high p130 levels have been 
found in rctinomas (benign retinal tumors) and not in ncarb) retinoblastoma. This 
finding suggests the progression of retinoma to retinoblastoma rna) be linked to the lack 
of pI 30. fhe p 130 might also be a tumor suppressor gene. Due to the discover) of 
consistent abnormalities in other chromosomes. the deletion of RB-I rna) not be enough 
for retinoblastoma to occur (MacPherson. 2008). 
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Retinoblastoma Diagnosis & Treatment 
Retinoblastoma is generally diagnosed using the results of a fundoscopy exam 
and sometimes with the aid of ultrasound, magnetic resonance imaging (MRI) and/or 
computed tomography (CT). Ocular fundoscopy is the process in which, under general 
anesthesia. the retina is observed using an indirect ophthalmoscopy. The lesion can be 
seen as a white twnor surrounded with irregularly arranged blood vessels. An ocular 
ultrasound expresses a mass made up of fine calcifications. When there is local extension 
of Rb. MRI is usually used to illustrate extensions of the twnor into the optic nerve, 
anterior chamber, and fat of the orbital. Intraocular tumors that are higher in density than 
the vitreous body are typically observed in using CT (Aertcs, 2006). 
Treatment is dependent upon the follo"'ring types of retinoblastoma and stages of 
the disease; bilateral, unilateral, multifocaJ, unifocal. number oftwnors, size of tumors. 
and disease extension. Two classification systems that are used to group retinoblastoma 
are the Reese Ellsworth classification and the ABC classification. After Rb staging has 
been determined. treatment is decided and may include a number of the following: 
enucleation, external beam radiation therapy. cryotherapy, tTanspupillary thern1olherapy. 
laser photocoagulation. brachytherapy, chemotherapy (Aertes, 2006). 
Enucleation (the complete removal of the eyeball) is recommended in certain 
situations that include large tumors, retinal detachment. and loss of functional vision. 
Although it can be traumatic, it is usually successful. Also successful is external beam 
radiation therapy: however, there are many adverse side effects that include secondary 
non-ocular malignancies, cataracts, radiation retinopathy (bleeding and exudates of the 
retina), impaired vision, temporal bone suppression and deformities (De Pouer, 2002; 
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Abramson and Servodidio, 1997). In an attempt to a\oid enucleation and external beam 
radiation therapy, first-line chemotherapy is often used followed by local treatment (De 
Potter. 2002). 
Chemotherapy options include chemotherapy injections into the bloodstream 
(intravenous), subconjunctival chemotherapy (applied locally underneath the conjunctiva) 
and systemic chemotherapy (taken orally or injected into the muscles). Chemotherapy 
drugs commonly used for treating Rb include carboplatin, vincristine, and/or etoposide. 
After these tumors ha\C been chemoreduced they can be treated ~ith the more local 
treatments (De Potter, 2002). 
Laser photocoagulation is the procedure of shining a beam of light through the 
pupil to pennanently destroy the vessels feeding the tumor. Transpupillary 
thennotherapy uses an infrared laser to induce hyperthermia on the tumor. Adverse side 
effects can include optic disc and focal iris atrophy. Cryotherapy is a procedure that 
denatures smaller retinoblastoma tumors by freezing them. Brach)- therapy is the suture 
of an iodine-125 ( 125f) plaque to the tumor and subsequent removal to reduce tumor size. 
This procedure aims to reduce excess radiation and is often used in place of external 
beam radiation (De Potter, 2002; Abramson and Servodidio. 1997; Kufe. et al., 2003). 
Cannabinoids 
Several studies have examined the medicinal properties of Cannabis's main active 
component THC (tetrahydrocannabinol). However. due to its psychoactive properties 
and the build-up of resistance. other cannabinoids have been investigated to find a more 
effective phannaceutical. A group of cannabinoids that are T J JC metabolites actually 
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lack psychoactive effects and are caJ ied cannabinoid acids. These acids include all of the 
cannabinoids' carboxylic acid metabolites and their man-made analogs. The primary 
metabolite of the cannabinoid acids, derived after the oxidative metabolism ofTHC. is 
THC-11-oic acid. I lowever, to make it more potent for pharmaceutical uses. the 
synthetic analog of THC-11-oic acid called ajulemic acid (dimethylheptyl-TIIC-11-oic 
acid) or AJA was developed (Structure sho'W'll in Figure I) (Zurier). AJA has been found 
to relieve pain, reduce inflammation. and have anti-tumor effects without producing 
psychoactivity (Recht, 200 I). 
Ajulemic acid (C25H3604) has a molecular weight of 400.55 g/mol and is stable as 
a white crystalline solid. It is easily dissolved in many organic solvents and aqueous 
buffers 'With a pii above 8 (Burstein. 2005). 
COOH 
Figure 1. tructure of Ajulcmic Acid 
There has been much research conducted in an attempt to determine AJA 's mode 
of action. Although there are still many unknowns, several propositions have been made. 
First!), it has been identified that AJA is highly stereospecific points to the idea that its 
mechanism is receptor mediated (Burstein, 2004). There is evidence that AJA 
moderately binds to CB1 and CB2 receptors; however, this is contradictory with AJA"s 
non-psychoactivity (Burstein, 2005). CB 1 receptors are found throughout the peripheral 
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nervous system and the central nervous system. The areas in which the receptors are 
most heavil:> expressed (the hippocampus. cortex, basal ganglia_ cerebellum, and spinal 
cord) account for the memory. cognitive, and movement effects of cannabinoids. The 
actual binding to the CB receptors activate G-proteins that affect many signal pathways 
b; activation or inhibition (CN forum). 
When the cannabinoid receptors are activated by TI I C. the activated 0-proteins 
inhibit calcium channels dependent upon voltage gradients. sodium channels. and 
adenylate cyclase. In addition. the G-proteins stimulate potassium channels and the 
MAPK signaling pathway. In all, the cell's cAMP concentration is decreased leading to 
neurotransmission inhibition. The sum of these affected pathways result in the euphoria 
effects involved in using Cannabis (CNSforum). Therefore. it has been suggested AJA 
may activate these receptors while antagonizing the pathway needed for the psychotropic 
effects (Brecht. 2005). In addition, there still may be other receptors with which AJA 
interacts, such as strychnine-sensitive a 1- and a 1P-glycine receptors (Ahrens. et al., 2008) 
or the isotope 'Y of the peroxisome proliferator-activated receptor (PPAR-y) (Ambrosio. et 
at.. 2007). Further research should be conducted to detem1ine the receptors to which 
AJA binds both directly and indirectly. 
Carhop/at in 
Carboplatin (CBP) is a chemotherapy drug that is currently being used in the 
treatment of several cancers including retinoblastoma. CBP (molecular weight 3 71.25 
g/mol) is made up of a platinum-coordinated complex and is toxic to cells by alkylating 




Figure 2. Structure of Carboplatin 
Not onJy can carboplatin be used with other chemotherapy drugs intravenously, it 
has also been used singularly as a periocular injection (Figure 2) (Schmack, eta!., 2006). 
However, a major side effect encountered with carboplatin periocular injections is 
ischemic optic neuropathy (Schmack, et aJ .. 2006). Another accepted use is the 
subconjunctival injection of carboplatin. Side effects for this procedure include 




Figure 3. Periocular carboplatin injection. 
From: Schmack: The American Journal of Ophthalmology, Volume 142(2).August 
2006.311. © 2006 Elsevier Inc. 
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Materials 
Ajulemic acid (AJA) 
Ajulemic acid (AJA). dimethylheptyi-Tl IC-11-oic acid was prepared in dimethyl 
sulfoxide (OMSO) to a final stock concentration of 10 mM. 
Carboplatin (CBP) 
Carboplatin (CBP) stock was obtained from Sigma-Aldrich and was prepared in 
sterile phosphate buffer saline (PB ) or ethanol (EtOI I) to a stock concentration of 10 
mM. 
Cell Culture 
Y -79 (human retinoblastoma) suspension cell line was obtained from A TCC and 
grov.n in RPMI-1640 medium containing a final concentration of 10% fetal bovine serum 
and was cultured at 37 C v.ith 5.0% C02. Primary mice microglia and astrocytes were 
obtained from UAMS. 
Methods 
MTSAssay 
Y -79 cell viability was determined by measuring mitochondrial activity using an 
MT assay composed of [3-(4.5-dimethylthiazone-2yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophen) I)-2II-tetrazolium] and an electron coupling reagent (phenazine 
methosulfate) (Promega). MT solution was prepared by adding 42 mg ofMT Reagent 
Powder to 21 mL of DPBS. mixed on stir plate for 15m in, and filter-sterilized through a 
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0.2 !lin filter. MTS (40 IlL) were added to each well of a 96-well plate. and the plate was 
incubated at 37"C for 1 bour. The plate was then read in a plate reader (TECAN infinite 
series) and absorbance was measured at wavelength of 490 nm. 
MTT Assay 
An MTT (3-(4.5-dimethylthiazone-2yl)-2,5-diphenyltetrazolium bromide) assay 
was used to assess cell viability of primary microglia and astrocytes. MTT solution was 
prepared by diluting MTT 1 :50 with culture medium. Cell culture media was removed 
from cells and replaced with 500 IlL MTT solution and incubated at 3 TC for one hour. 
MIT solution was removed and cells were lysed by adding 500 IlL DMSO/well. Plates 
were rocked for 30 min and read on a plate reader (TECAN infinite series) at570 nm. 
ELISA Assay 
Caspase-3 levels were measured using an enLyme-linked immunosorbent assay 
according to manufacturer's recommendations (BD Bioscience). 
Neuroprolection 
Mouse cortical neurons were obtained from Lonza. They were plated in 36 wells 
of a 96-well plate and cultured according to manufacturer's recommendations. Fourteen 
days after plating. cells were treated with either AJA, JNF-r (interferon gamma). both or 
neither as indicated for 72 hr. MTS assays were then run as previously described to 




In order to determine the ideal cell density at which Y -79 Rb cells grew the best 
and reacted most towards the treatment, multiple cell densities were investigated. The 
cells were plated in 5 various densities ranging from 4x 104 cells/well to 4x I 05 cells/well 
in 6 wells each of the 96-well plate. After 24 hr. wells 1-3 of each density were left 
untreated and wells 3-6 of each density were treated with 50 J..lM ajulemic acid. An MTS 
assay was used to measure the cell viability by assessing the mitochondrial activity. The 
MTS reagent is a chemical that reacts with an enzyme present when the mitochondria are 
active. This reaction yields a so luble purple precipitate that can be measured in intensity 
on a plate reader at 490 run. Cell viability was compared at each density with the 
untreated wells. Greatest cell viability loss due to AJA treatment was observed at the cell 
density 3.1 x 1 05 cells/well (Figure 4 ). 
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Figure 4. Cell Density. 
Y-79 Rb cells were plated with indicated densities and treated in triplicate with 50 ).I.M 
AJA. Cell viability was measured using MTS assay 72 hr later. Values represent the 
average cell viabi lity for triplicate cultures. Standard errors are indicated. Asterisks 
designate statistical significance of p<0.05. Greatest difference in viability between 
untreated and treated wells was observed at the cell density 3.1 xI 05 cells/well. 
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The Effects ofDMSO on the viability of Y-79 Rb cells 
In order to assess the effects of the solvent OM 0, in which AJA is dissolved. Y-
79 cells were plated in a 96-welJ plate at a density 3.lxl05 ceJVwell. Wells were treated 
in triplicate 24 hr later with the following increasing ajulemic acid concentration 
equivalents of dimethyl sulfoxide (DMSO): 50 eq, 75 eq, 100 eq. Cell viability was 
measured using an MTS assay. Our results indicate that DMSO does not significantly 






Figure 5. Y -79 Cultures with Dimethyl sulfoxide (DMSO) treatment. 
Cells were treated 24 hr after plating with DM 0 in equivalent volumes or AJA 
treatments as indicated to account for any cell death that was not caused by AJA. Cell 
viability was measured using MTS assay 72 hr later. Values represent the average cell 
viability for triplicate cultures. Standard errors are indicated. 
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Ajulemic Acid's Effect on Y- 79 Rb cell viability 
Y-79 cells were plated in a 96-well plate at a density 3. 1 xI 05 cells/well. Wells 
were treated in triplicate 24 hr later with the following increasing ajulernic acid (AJA) 
concentrations: 25 ~M, 50 ~M, 75 ~M. I 00 ~M. After 72 br, cell viability was measured 
using a MTS assay. Our data indicates significant cell death in Y-79 RB ce!Js when 




Figure 6. ignificant cell death observed in Y -79 cultures with AJA Treatment. 
Cells were treated in triplicate with the indicated AJA concentrations. Representative data 
are shown. MTS cell viability assay was run at 72 hr post-treatment. Values represent the 
average cell viability for triplicate cultures. tandard errors are indicated. Asterisks 
indicate statisticaJ significance of p<O.OS. 
Carboplalin 's E_ffec:t on r- 7 9 Rb cell viability 
Y -79 cells were plated in a 96-well plate at a density 3.1 x 105 cells/well. Wells 
vvere treated in triplicate 24 hr later with the follov. ing increasing chemotherapy drug 
carboplatin (CBP) concentrations: 25 j..tM. 50 j..tM, 75 j..tM, I 00 j..tM. An MT assay was 
used to measure the cell viability after 72 hr. Our results indicate that significant cell 










Figure 7. Y -79 cultures '""ith CBP Treatment. 
Cells were treated in triplicate with the indicated CBP concentrations. Representative 
data are shown. MT cell viability assay was run at 72 hr post-treatment. Values 
represent the average cell viabi lit) for triplicate cultures. tandard errors are indicated. 
Asterisks indicate stati stical significance ofp<0.05. 
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E.ffect of AJA on non-transformed neural-derived cells 
Primary mouse astrocytes and microglia were plated and after 24 hr. treated in 
triplicate with increasing ajulemic acid concentrations of 50 )..lM, 100 )..lM, and 200 )..lM. 
Cell viability was measured at 24 hr using an MTT (3-(4,5-dimethylthiazone-2yl)-2.5-
diphenylletrazolium bromide) assay. The MTT reagent reacts with a mitochondrial 
enzyme that is active when the cell is alive and the chemical reaction yields an insoluble 
purple precipitate. Once the cell is lysed, the precipitate is released and the assay 
concentration can be measured on a plate reader at 570 nm. The results indicate that AJA 
concentrations between 100 and 200 11M become toxic to astrocytes (Figure 8 - Chavis 















Figure 8. Ajulemic acid becomes toxic to non-transformed neural-derived cells at 
concentrations between 100 and 200 fJ M. Cells were plated in triplicate and treated 
with the indicated concentrations of AJA. MTT cell viability assays were run at 24 hr 
post-treatment. Standard errors are indicated. Asterisks indicate statistical signHicance 
of p < 0.05 (Chavis and Tull, 2007). 
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Possible 1\'europrotection ·with Ajulemic Acid 
Primary mouse conical neurons were plated in a 96-wcll plate. Neurons were 
treated with 500 units/ML interferon gamma (INF-y). ignificant cell death was 
observed. Mice neurons were pretreated v.ith 40 J.lM AJA and then treated v.ith 500 
units/mL l F-y. Although not significant, less cell death was observed in the cel ls 
pretreated with AJA versus the control. Mice neurons were treated with 40 J.lM of AJA 
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Figure 9. Neuroprotection with Ajulemic Acid. 
ignificant cell death occurred when interferon gamma ( lFN-y) was used to treat mouse 
cortical neurons. When treatment included both IFN-y and AlA together. a lower amount 
of cell death was observed. There was also a lower amount of cell death observed when 
the AJA only treatment was used. MT cel l viabi lity assa} was run at 
72 hr post-treatment. Values represent the average for triplicate cultures. tandard errors 
are indicated. Asterisks indicate statistical significance of p < 0.05 (llurst, 2008). 
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Potential Apoptosis Mechanism ofAjulemic Acid 
Expression of caspase-3. an enzyme activated during the apoptotic cascade. was 
measured by ELI A. The results indicate that caspase-3 has been expressed in SK-E 





Untreated 1 AJA Pretreat 
Figure 10. Caspase-3 ELI A. 
K-E Ewing's sarcoma cells were pretreated v .. ith 40 jlM ajulemic acid and \vere 
measured for caspase-3 expression using ELI A assay. Indicated amounts of caspase-3 




The medicinal use of Cannabis· active ingredient THC (tetrahydrocannabinol) 
has attracted much attention. However. its psychotropic effects. although not usually 
considered addictive. keep it from being socially accepted. Therefore. there has been a 
large amount of recent research on its synthetic analog ajulemic acid (AJA) "'hich docs 
not cause psychoactive effects. This research has shown AJA 's connection to pain 
reduction. anti-inflammatory properties, and tumor reduction without psychoactive 
effects. Up until no\.\, there had been no prior research done on the effects of AJA on 
retinoblastoma. a neural derived cancerous tumor of the retina. 
Cells from human retinoblastoma cell line Y -79 were treated \\ith various 
concentrations from 25 to 100 ~M of AJA. Complete cell death was observed after 72 hr 
using an MTS assay to measure viabilit). There is significant evidence that ajulemic acid 
is a potent retinoblastoma tumor ce ll suppressor. 
Ajulemic acid was also used to treat primary mouse astrocy1es and microglia. 
Only AJA concentrations above I 00 ~M induced significant cell death. Therefore. AJA 
has been shown to significantly kill the Rb tumor cells at concentrations below 100 ~LM 
""ithout inducing cell death to the surrounding neuroglial tissue. 
Preliminal) data suggest ajulemic acid may also be neuroprotectivc. ignificant 
cell death of primary mouse neurons occurred when treated with the C) tokine interferon 
gamma (INF-y) which causes cell apoptosis. However. V¥hen neurons were pretreated 
\\ith 40 ~M AJA and were then introduced to the interferon gamma. less cell death 
occurred. Although the data was not statistically significant, a greater number of trials 
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with larger sample sizes may result in a more concrete answer to AJA's ability to protect 
neurons from immune responses such as INF-y. 
Ajulemic aci.d's effects on RB cells may be induced through apoptotic 
mechanisms. The expression of caspase-3 indicates that apoptosis did occur in cells 
treated with AJA. Apoptosis is a preferable method of cell death over necrosis because 
cell rupture. as it occurs in necrosis, can cause leakage of lysosomal enzymes that may be 
deadly to nearby cells. 
In our cell model, at equal concentrations ajulemic acid is more toxic to the Rb 
tumor cells than carboplatin, a current chemotherapy drug used for retinoblastoma 
treatment. Future research should investigate the effects of Rb tumor viability vvith lower 
ajulemic acid concentrations. Lower concentrations of AJA with the same loss of twnor 
cell viability could be a more beneficial treatment. 
There is great potential for the movement of AJA in the direction of Rb treatment. 
Plans include continuing the research on AJA and its effectiveness as a tumor therapeutic 
in the hopes that one day, AJA may be a solution for retinoblastoma patients. 
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